Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim’s Ingelvac PRRS MLV used to treat one billion pigs

Boehringer Ingelheim’s Ingelvac PRRS MLV used to treat one billion pigs

3rd October 2016

Boehringer Ingelheim has announced that more than one billion sows and pigs have now been treated with its Ingelvac PRRS MLV vaccine.

Originally launched in the US in 1994, the vaccine – which protects against porcine reproductive and respiratory syndrome (PRRS) – is now available in 19 countries across Europe, North America and Asia.

This modified live vaccine works to prevent PRRS type II, one of the most severe swine diseases in the world, affecting an estimated 1.5 billion pigs globally each year.

Over the last two decades, Ingelvac PRRS MLV has become a trusted brand, allowing veterinarians and farmers to increase the productivity of their farms by reducing or eliminating the negative outcomes of PRRS infections.

Not only does the prevention of PRRS and other diseases through vaccination lead to more efficient livestock farming, but it can also reduce the need for antibiotics, leading to an improved quality of food from animal origin.

Ingelvac PRRS MLV remains one of Boehringer Ingelheim's most important animal health brands, alongside Ingelvac Circoflex, Metacam and Duramune.

With over 20 years of experience within the animal health market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current animal health roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801826244-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.